ASX:BD1

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

BARD1 Life Sciences

Executive Summary

BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has BARD1 Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BD1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.7%

BD1

1.3%

AU Healthcare

0.2%

AU Market


1 Year Return

13.3%

BD1

0.7%

AU Healthcare

-7.8%

AU Market

Return vs Industry: BD1 exceeded the Australian Healthcare industry which returned 0.7% over the past year.

Return vs Market: BD1 exceeded the Australian Market which returned -7.8% over the past year.


Shareholder returns

BD1IndustryMarket
7 Day9.7%1.3%0.2%
30 Day13.3%0.4%0.4%
90 Day30.8%13.5%13.3%
1 Year13.3%13.3%3.8%0.7%-4.1%-7.8%
3 Year218.6%209.1%9.2%-0.6%17.3%1.8%
5 Yearn/a16.7%-0.1%38.1%8.2%

Price Volatility Vs. Market

How volatile is BARD1 Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BARD1 Life Sciences undervalued compared to its fair value and its price relative to the market?

5.68x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BD1 is unprofitable, so we can't compare its PE Ratio to the AU Healthcare industry average.

PE vs Market: BD1 is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BD1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BD1 is overvalued based on its PB Ratio (5.7x) compared to the AU Healthcare industry average (1.4x).


Next Steps

Future Growth

How is BARD1 Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BARD1 Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BARD1 Life Sciences performed over the past 5 years?

-6.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BD1 is currently unprofitable.

Growing Profit Margin: BD1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BD1 is unprofitable, and losses have increased over the past 5 years at a rate of 6.2% per year.

Accelerating Growth: Unable to compare BD1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BD1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (4.3%).


Return on Equity

High ROE: BD1 has a negative Return on Equity (-29.29%), as it is currently unprofitable.


Next Steps

Financial Health

How is BARD1 Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: BD1's short term assets (A$8.7M) exceed its short term liabilities (A$526.0K).

Long Term Liabilities: BD1's short term assets (A$8.7M) exceed its long term liabilities (A$31.7K).


Debt to Equity History and Analysis

Debt Level: BD1 is debt free.

Reducing Debt: BD1 currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BD1 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BD1 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 26.8% each year


Next Steps

Dividend

What is BARD1 Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BD1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BD1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BD1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BD1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BD1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.08yrs

Average management tenure


CEO

Leearne Hinch

3.75yrs

Tenure

AU$442,442

Compensation

Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of BARD1 Life Sciences Limited since November 7, 2016. Dr. Hinch is a biotechnology executive and consultant ...


CEO Compensation Analysis

Compensation vs Market: Leearne's total compensation ($USD316.32K) is about average for companies of similar size in the Australian market ($USD269.15K).

Compensation vs Earnings: Leearne's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Leearne Hinch
Chief Executive Officer3.75yrsAU$442.44kno data
Irmgard Irminger-Finger
Founder9.83yrsAU$150.00k5.16%
A$ 3.8m
Peter Gunzburg
Managing Directorno dataAU$75.28k1.64%
A$ 1.2m
Tony Di Pietro
CFO & Company Secretary0.083yrno datano data
Carl Stubbings
Chief Operating Officer0.083yrno datano data

0.08yrs

Average Tenure

Experienced Management: BD1's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Irmgard Irminger-Finger
Founder9.83yrsAU$150.00k5.16%
A$ 3.8m
Peter Gunzburg
Managing Directorno dataAU$75.28k1.64%
A$ 1.2m
Philip Powell
Independent Non-Executive Director1.17yrsAU$2.14k0.21%
A$ 155.0k
Geoffrey Cumming
Non-Executive Chairman0.083yrno datano data
Robert Johnston
Independent Non-Executive Director1.17yrsAU$2.14k0.24%
A$ 176.7k
Allan Cripps
Non-Executive Director0.58yrno datano data
Samuel Janes
Member of Advisory Board3.08yrsno datano data
Helen Fisher
Non-Executive Director0.083yrno datano data

1.2yrs

Average Tenure

Experienced Board: BD1's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

BARD1 Life Sciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BARD1 Life Sciences Limited
  • Ticker: BD1
  • Exchange: ASX
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$74.230m
  • Shares outstanding: 2.39b
  • Website: https://www.bard1.com

Location

  • BARD1 Life Sciences Limited
  • Unit 202, 39 Mends Street
  • Level 2
  • South Perth
  • Western Australia
  • 6151
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BD1ASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2016
EGQDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2016
BD1CHIA (Chi-X Australia)YesOrdinary SharesAUAUDJun 2016

Biography

BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a screening test fo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/06 10:44
End of Day Share Price2020/08/06 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.